tiprankstipranks
Biogen (BIIB)
NASDAQ:BIIB

Biogen Stock Analysis & Ratings

BIIB Stock Chart & Stats

Day’s Range$0 - $0
52-Week Range$187.16 - $372.12
Previous Close$211.93
Volume2.95M
Average Volume (3M)1.11M
Market CapN/A
Enterprise ValueN/A
P/E Ratio21.7
Beta0.54
Next EarningsJul 26, 2022
Dividend YieldN/A
Smart Score10


Financials

Yearly

P/E Ratio Range

The price to earnings ratio. This is used by investors to assess a stock’s market price relative to its earnings.

---

Risk Analysis

Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy

Product Monthly Users

Sorry, No Data Available
There is no website visitor data available for this stock.

---

BIIB FAQ

What was Biogen’s price range in the past 12 months?
Biogen lowest stock price was $187.16 and its highest was $372.12 in the past 12 months.
    What is Biogen’s market cap?
    Currently, no data Available
    What is Biogen’s price target?
    The average price target for Biogen is $245.35. This is based on 22 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
    The highest analyst price target is $320.00 ,the lowest forecast is $185.00. The average price target represents 15.77% Increase from the current price of $211.93.
      What do analysts say about Biogen?
      Biogen’s analyst rating consensus is a ‘Moderate Buy. This is based on the ratings of 22 Wall Streets Analysts.
        When is Biogen’s upcoming earnings report date?
        Biogen’s upcoming earnings report date is Jul 26, 2022 which is in 31 days.
          How were Biogen’s earnings last quarter?
          Biogen released its earnings results on May 03, 2022. The company reported $3.62 earnings per share for the quarter, missing the consensus estimate of $4.34 by -$0.72.
            Is Biogen overvalued?
            According to Wall Street analysts Biogen’s price is currently Undervalued. Get more investment ideas with TipRanks Premium
              Does Biogen pay dividends?
              Biogen pays a Notavailable dividend of $22.23 which represents an annual dividend yield of N/A. Biogen’s last Notavailable dividend payment was on Feb 01, 2017. Biogen’s upcoming ex-dividend date is Feb 02, 2017
                What is Biogen’s EPS estimate?
                Biogen’s EPS estimate is $4.11.
                  How many shares outstanding does Biogen have?
                  Biogen has 146,452,010 shares outstanding.
                    What happened to Biogen’s price movement after its last earnings report?
                    Biogen reported an EPS of $3.62 in its last earnings report, missing expectations of $4.34. Following the earnings report the stock price went down -0.781%.
                      Which hedge fund is a major shareholder of Biogen?
                      Among the largest hedge funds holding Biogen’s share is PRIMECAP Management Co. It holds Biogen’s shares valued at 3B.

                        ---

                        Biogen Stock Analysis

                        Smart Score
                        10
                        Outperform
                        1
                        2
                        3
                        4
                        5
                        6
                        7
                        8
                        9
                        10
                        Price Target
                        $245.35
                        ▲(15.77% Upside)
                        Moderate Buy
                        The Biogen stock analysis is based on the TipRanks Smart Score which is derived from 8 unique data sets including Analyst recommendations, Crowd Wisdom, Hedge Fund Activity, Media Sentiment and multiple Technical stock factors. The Smart Score is a quantitative, data-driven rating system and does not include human intervention.
                        Learn more about TipRanks Smart Score

                        Company Description

                        Biogen

                        Incorporated in 1978, Massachusetts-based Biogen, Inc. is a biopharmaceutical company, which discovers, develops, and delivers therapies for the treatment of neurological and neurodegenerative diseases. It offers TECFIDERA, AVONEX, PLEGRIDY, TYSABRI, VUMERITY, and FAMPYRA for the treatment of multiple sclerosis; SPINRAZA for the treatment of spinal muscular atrophy; and FUMADERM for the treatment of severe plaque psoriasis.

                        ---
                        Similar Stocks
                        Company
                        Price & Change
                        Follow
                        Roche Holding
                        Acorda Therapeutics
                        AbbVie
                        Pfizer
                        Ionis Pharmaceuticals

                        Popular Stocks

                        ---
                        What's Included in PREMIUM?
                        Make informed decisions based on Top Analysts' activity
                        Know what industry insiders are buying
                        Get actionable alerts from top Wall Street Analysts
                        Find out before anyone else which stock is going to shoot up
                        Get powerful stock screeners & detailed portfolio analysis